Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more
Market Cap & Net Worth: Genmab A/S (GNMSF)
Genmab A/S (PINK:GNMSF) has a market capitalization of $11.47 Billion ($11.47 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #1531 globally and #1151 in its home market, demonstrating a -5.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genmab A/S's stock price $186.15 by its total outstanding shares 61599307 (61.60 Million).
Genmab A/S Market Cap History: 2015 to 2025
Genmab A/S's market capitalization history from 2015 to 2025. Data shows growth from $8.01 Billion to $11.47 Billion (7.19% CAGR).
Genmab A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genmab A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.61x
Genmab A/S's market cap is 0.61 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.67x
Genmab A/S's market cap is 1.67 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $8.01 Billion | $1.13 Billion | $763.51 Million | 7.07x | 10.49x |
| 2016 | $9.81 Billion | $1.82 Billion | $1.19 Billion | 5.40x | 8.26x |
| 2017 | $10.12 Billion | $2.37 Billion | $1.10 Billion | 4.28x | 9.17x |
| 2018 | $9.91 Billion | $3.03 Billion | $1.47 Billion | 3.27x | 6.73x |
| 2019 | $13.33 Billion | $5.37 Billion | $2.17 Billion | 2.48x | 6.15x |
| 2020 | $25.78 Billion | $10.11 Billion | $4.76 Billion | 2.55x | 5.42x |
| 2021 | $24.06 Billion | $8.48 Billion | $2.96 Billion | 2.84x | 8.14x |
| 2022 | $26.33 Billion | $14.60 Billion | $5.45 Billion | 1.80x | 4.83x |
| 2023 | $19.45 Billion | $16.47 Billion | $4.35 Billion | 1.18x | 4.47x |
| 2024 | $13.09 Billion | $21.53 Billion | $7.84 Billion | 0.61x | 1.67x |
Competitor Companies of GNMSF by Market Capitalization
Companies near Genmab A/S in the global market cap rankings as of March 18, 2026.
Key companies related to Genmab A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Genmab A/S Historical Marketcap From 2015 to 2025
Between 2015 and today, Genmab A/S's market cap moved from $8.01 Billion to $ 11.47 Billion, with a yearly change of 7.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $11.47 Billion | -12.40% |
| 2024 | $13.09 Billion | -32.69% |
| 2023 | $19.45 Billion | -26.15% |
| 2022 | $26.33 Billion | +9.47% |
| 2021 | $24.06 Billion | -6.68% |
| 2020 | $25.78 Billion | +93.45% |
| 2019 | $13.33 Billion | +34.54% |
| 2018 | $9.91 Billion | -2.10% |
| 2017 | $10.12 Billion | +3.14% |
| 2016 | $9.81 Billion | +22.50% |
| 2015 | $8.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Genmab A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.47 Billion USD |
| MoneyControl | $11.47 Billion USD |
| MarketWatch | $11.47 Billion USD |
| marketcap.company | $11.47 Billion USD |
| Reuters | $11.47 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.